Daré Bioscience Reports Q3 2026 Financial Results
Daré Bioscience reported Q3 2026 revenue of approximately $48,000 compared to approximately $2,300 in Q3 2025, with the increase attributable to research and development services revenue under Gates Foundation agreements and initial Flora Sync LF5 sales that began in July 2026. Net loss improved to approximately $3.2 million from approximately $3.6 million in the prior year period, while EPS improved to $(0.18) from $(0.28). The company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q4...
Key takeaways
Revenue increased to approximately $48,000 in Q3 2026 from approximately $2,300 in Q3 2025, driven by Gates Foundation research services revenue and initial Flora Sync LF5 sales
Net loss improved to approximately $3.2 million from approximately $3.6 million year-over-year; EPS improved to $(0.18) from $(0.28)
Selling, general and administrative expenses remained relatively flat at approximately $2.6 million versus approximately $2.5 million in Q3 2025
Research and development expenses decreased to approximately $0.3 million from approximately $1.2 million, primarily due to decreased costs for Sildenafil Cream, DARE-LARC1, and Ovaprene programs
Cash position was approximately $11.5 million with working capital of approximately $3.2 million as of September 30, 2026
DARE to PLAY Sildenafil Cream prescription dispensing activities commenced in November 2026 across 48 states and Washington, D.C.
Flora Sync LF5 has generated orders from 27 states with a 4.9-star consumer review rating and first provider office reorder
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow DARE in real time
Get material earnings, filing, IR, and earnings-call alerts by email.